BFM
IMCR icon

Boothbay Fund Management’s Immunocore IMCR Stock Holding History

Boothbay Fund Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,826
Closed -$253K – 2018
2021
Q3 		$253K Buy
6,826
+770
+13% +$26K 0.01% 1420
2021
Q2 		$236K Buy
+6,056
New +$234K 0.01% 1417

Other funds holding IMCR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BCPEMI
Bain Capital Public Equity Management II Boston, Massachusetts $62.1M AUM 25.46% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Boothbay Fund Management's IMCR Position: Q4 2021 in Review

Boothbay Fund Management sold out of Immunocore (IMCR) in Q4 2021, closing a stake of 6,826 shares — an estimated $253K sold.

Boothbay Fund Management first reported a position in IMCR in Q2 2021 and held it in 2 quarters. The position peaked at $253K in Q3 2021. 49 funds tracked by Wall St. Rank hold IMCR as of Q4 2021.

  • Boothbay Fund Management reported no remaining Immunocore position as of Q4 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 6,826 Immunocore shares in Q4 2021, an estimated $253K.
  • Boothbay Fund Management first reported a position in Immunocore in Q2 2021 and held it in 2 quarters.
  • Boothbay Fund Management's Immunocore position peaked at $253K in Q3 2021.
  • 49 funds tracked by Wall St. Rank held Immunocore as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.